Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – Adding the multitargeted tyrosine kinase inhibitor sunitinib (Sutent; Pfizer) to docetaxel did not improve clinical outcomes when used in the first-line setting in…
NEW YORK (Reuters Health) – Despite widespread use of antipsychotics in children, evidence regarding the comparative benefits and harms of first-generation (FGAs) and second-generation antipsychotics (SGAs) are “limited,”…
NEW YORK (Reuters Health) – Giving statins before a surgery lowers the risk of heart attack in statin-naïve patients, according to a new meta-analysis. The drugs also reduced…
NEW YORK (Reuters Health) – Systematic collection of extensive family history can improve the risk assessment of cardiovascular disease in primary care, according to a report in the…
NEW YORK (Reuters Health) – Transfusions appear to be associated with an increased risk of necrotizing enterocolitis in neonates, researchers from Canada report in the February 20th online…
NEW YORK (Reuters Health) – Postcataract surgery endophthalmitis rates in the United States declined slightly between 2003 and 2004, but there is still room for improvement, according to…
NEW YORK (Reuters Health) – Some elderly patients with unresected non-small cell lung cancer (NSCLC) may do better with chemoradiotherapy (CRT) than with radiotherapy (RT) alone. However, low…
NEW YORK (Reuters Health) – Newer generation everolimus-eluting stents (EES) are significantly less likely to prompt very late stent thrombosis than are the first generation of drug-eluting stents…
NEW YORK (Reuters Health) – For reversal of type 1 hepatorenal syndrome, treatment with noradrenaline seems to work as well as terlipressin and is a lot less expensive,…
NEW YORK (Reuters Health) – The everolimus-eluting stent and the sirolimus-eluting stent are equally safe and efficacious in patients with coronary artery disease, the SORT OUT IV Trial…
